Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus ointment vs timolol solution for post-acne erythema
IRCT20151123025202N33Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Nov 2023
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of tacrolimus and timolol in acne vulgaris and Postinflammatory erythema (PIE), sponsored by Hamadan University of Medical Sciences. Started Nov 2023; status: completed.
02
Drugs
tacrolimustimolol
03
Conditions
acne vulgarisPostinflammatory erythema (PIE)
Beyond the preview
Go deeper on IRCT20151123025202N33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151123025202N33.